Show simple item record

dc.contributor.authorFessas, P
dc.contributor.authorLee, H
dc.contributor.authorIkemizu, S
dc.contributor.authorJanowitz, T
dc.date.accessioned2017-07-10T12:17:21Z
dc.date.available2017-07-10T12:17:21Z
dc.date.issued2017-04
dc.identifier.issn0093-7754
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/265230
dc.description.abstractT cell checkpoint inhibition has a profound impact on cancer care and the two Programmed cell death protein 1 (PD-1) targeted antibodies nivolumab and pembrolizumab have been leading this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature. We acknowledge the limitations of such comparisons, but suggest that based on the available data, differences in clinical trial outcomes between nivolumab and pembrolizumab are more likely drug-independent than drug-dependent.
dc.description.sponsorshipWellcome Trust Translational Medicine and Therapeutics Grant RJAG/076
dc.language.isoen
dc.publisherElsevier
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectNivolumab
dc.subjectPembrolizumab
dc.subjectPD-1
dc.subjectT-cell checkpoint
dc.titleA Molecular and Preclinical Comparison of the PD-1 targeted T cell Checkpoint Inhibitors Nivolumab and Pembrolizumab
dc.typeArticle
prism.endingPage140
prism.issueIdentifier2
prism.publicationNameSeminars in Oncology
prism.startingPage136
prism.volume44
dc.identifier.doi10.17863/CAM.11255
dcterms.dateAccepted2017-06-27
rioxxterms.versionofrecord10.1053/j.seminoncol.2017.06.002
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
rioxxterms.licenseref.startdate2017-06-27
dc.identifier.eissn1532-8708
rioxxterms.typeJournal Article/Review
cam.issuedOnline2017-07-04
cam.orpheus.successThu Jan 30 12:53:44 GMT 2020 - Embargo updated
rioxxterms.freetoread.startdate2018-07-04


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International